The effect of Rosa Canina hydroalcoholic extract on ventricular arrhythmias in heart failure patients with implantable cardioverter-defibrillators: A Randomized Clinical Trial

Background: Heart failure (HF) transpires when the heart is unable to pump sufficient blood. A key cause of ventricular arrhythmias in HF is oxidative stress and prolonged inflammation. Few clinical studies exist on the heart-related effects of Rosa Canina, especially in high-risk patients with implantable cardioverter-defibrillators (ICDs).Objectives: This study was designed to assess whether Rosa Canina extract could reduce ventricular arrhythmias in these patients.Methods: This double-blind, randomized clinical trial was conducted on ۱۰۰ patients with HF and ICDs. Patients were randomly assigned to two groups: one received Rosa Canina extract tablets (۲۵۰ mg, two tablets twice daily) and the other received placebo tablets of similar shape and color (two tablets twice daily). The extract was prepared and standardized in the pharmacognosy laboratory using the wet granulation method. Patients were followed for one month, and the number of ventricular arrhythmias, PVCs, ICD shocks, and hospital admissions was recorded.Results: The Rosa Canina group had significantly lower PVC frequency (۲۲% vs. ۵۸%; P<۰.۰۰۱) and lower ICD shock frequency (۱۴% vs. ۴۰%; P=۰.۰۰۳) compared to the placebo group. In contrast, hospitalization rates did not differ significantly between groups (P = ۰.۱۸۰). Furthermore, ۸۶% of patients in the Rosa Canina group achieved a successful outcome, compared to ۶۰% in the placebo group (P = ۰.۰۰۳).Conclusion: The findings suggest that Rosa Canina extract may be an affordable and helpful supplement to standard treatment for reducing serious complications in heart failure patients.

کلیدواژه ها:

Heart Failure ، Arrhythmia ، Rosa Canina ، Device Lead Extraction ، Implantable Cardioverter Defibrillator (ICD)